UK Asthma and COPD Drugs Market Insight
Published: 30 May 2026 | Report Format: Electronic (PDF)
The UK asthma and COPD drugs market size is rapidly expanding, at a 5.61% CAGR, and the biologics, inhalers, and digital respiratory therapies.
UK Asthma and COPD Drugs Market Insights Forecasts to 2035
- The UK Asthma and COPD Drugs Market Size Was Estimated at USD 2.63 Billion in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.61% from 2025 to 2035
- The UK Asthma and COPD Drugs Market Size is Expected to Reach USD 4.54 Billion by 2035
Notable Insights for UK Asthma and COPD Drugs Market
- The combination inhaler segment accounts for roughly 48% market share in the asthma and COPD drugs market of the United Kingdom owing to the presence of dual and triple therapies, patient adherence, and increased demand for respiratory treatments, backed by NHS England and £3.8 billion respiratory healthcare investments.
- The COPD application area contributes to approximately 42% demand share in the United Kingdom owing to the prevalence of chronic respiratory diseases, growing aging population, and expansion of healthcare expenditures, backed by Asthma + Lung UK and £2.9 billion investments in pulmonary healthcare services.
- More than £190 billion annual investment is made by the United Kingdom healthcare sector in promoting advanced respiratory treatments, biologic drugs, and precision medicine solutions, backed by UK Department of Health and Social Care and £6.2 billion respiratory innovations investments.
- The biological drugs segment captures approximately 24% demand share in the asthma and COPD drugs market of the United Kingdom owing to the growing use of severe asthma treatment and targeted immunotherapies, backed by National Institute for Health and Care Excellence and £3.1 billion investments in biologic drugs.
Download the eBook (ToC)
Why Buy This Report
- Learn all about the UK market for asthma and COPD drugs which include combination inhalers, biological treatments, bronchodilators, corticosteroids, smart inhalers, and other advanced respiratory solutions.
- Discover how biological drugs, artificial intelligence-driven respiratory monitoring devices, digital inhalation systems, precision medicine, and connected health platforms are revolutionizing the UK asthma and COPD drugs sector.
- Find the best investment prospects in respiratory drugs, biological drug manufacturing, digital respiratory care solutions, smart inhalers, and pulmonary disease management.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the UK asthma and COPD drugs market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Asthma and COPD Drugs Market
- GlaxoSmithKline
- AstraZeneca
- Novartis
- Boehringer Ingelheim
- Sanofi
- Regeneron Pharmaceuticals
- Teva Pharmaceutical Industries
- Chiesi Farmaceutici
- Others
Recent Developments:
- In March 2026, AstraZeneca strengthened United Kingdom asthma and COPD drugs market through biologic respiratory therapies and precision treatment platforms, supported by $6.5Billion respiratory R&D investments, enhancing asthma control, COPD management, and personalized patient care across UK healthcare systems.
- In October 2025, GSK strengthened United Kingdom asthma and COPD drugs market through next-generation inhalation therapies and respiratory biologics, supported by $5.8Billion pharmaceutical R&D investments, enhancing treatment adherence, disease management, and respiratory patient outcomes across UK healthcare infrastructure.
Market Segmentation:
United Kingdom Asthma and COPD Drugs Market, By Drug Class
- Bronchodilators
- Inhaled Corticosteroids
- Combination Therapies
- Biologics
- Others
United Kingdom Asthma and COPD Drugs Market, By Disease Type
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
United Kingdom Asthma and COPD Drugs Market, By Route of Administration
- Inhalation
- Oral
- Injectable
- Others
United Kingdom Asthma and COPD Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Expert Views:
The United Kingdom asthma and COPD drugs market is anticipated to experience significant growth in the coming years due to an increase in the prevalence of respiratory diseases, growing acceptance of biologics, and increased investment in advanced respiratory care solutions.
Author: Govind and Krishna By Spherical Insights and Consulting